TORONTO, ONTARIO -- (Marketwired) -- 05/17/13 -- Biologix Hair Inc. (OTCBB: BLGX) (OTCQB: BLGX) has appointed Mark Maybank to the Company's Board of Directors. Mr. Maybank will serve as an independent, non-executive Director.
Mark Maybank is an active investor, director and advisor. He is currently Chairman of Fleet Canada Inc., a Canadian aerospace company. He was recently the Chief Operating Officer and Director of Canaccord Financial Inc. and President and COO of Canaccord Genuity Corp. Mr. Maybank also served in various other capacities with Canaccord companies including Deputy Global Head of Capital Markets, Director of Canaccord's US and UK regulated subsidiaries and Executive VP, Managing Director, and Global Head of Research.
Previously, he was the COO and Executive VP, Business Development of Itemus Inc, an Internet and ecommerce company. Mr. Maybank currently serves as Co-Chair of Gold Medal Plates, is a member of the corporate advisory board of the Art Gallery of Ontario and is active on a number of other corporate boards.
Mr. Maybank holds his Chartered Accountant and Chartered Business Valuator designations. He earned a Bachelor of Commerce degree from the University of Alberta.
Biologix Chairman Ron Holland stated: "I look forward to working with Mark Maybank on our Board of Directors and appreciate his willingness to contribute to the Company in this manner. I am confident his knowledge and experience will prove quite valuable to the continued growth of Biologix Hair.
"The Biologix Board of Directors is now comprised of seven members, four of which are independent, non-executive Directors. This enables Biologix to proceed with the implementation of corporate governance committees and internal controls and further advances our NYSE Markets listing process."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.
Most Popular Stories
- Hezbollah Chief's Assassination Claimed by Sunni Group
- Allstate Seeks to Invest in Minority Firms
- SpaceX's Satellite Launch Is 'Game-Changer'
- Latin Music Conference Turns 25
- U.S. Growth Stayed Steady During Shutdown, Fed Says
- Newtown Massacre Heard on 911 Recordings
- Reid Confident Congress to Pass Immigration Bill
- Guardian Pressured to Stop NSA Stories: Editor
- New Home Sales Shoot up 25 Percent in October
- Climate Change Early Warning System Urged